BioSpace News Archive

Inbiose, a leading biotech company active in the development of Human Milk Oligosaccharides, is pleased to announce that it has submitted its application for a Generally Recognized as Safe approval by the US Food & Drug Administration of four HMOs, specifically 6'-Sialyllactose, 3-Sialyllactose, Lacto-N-Tetraose and Lacto-N-neoTetraose.

NEUWAY Pharma announced the formation of its Scientific Advisory Board including leading drug delivery and drug development experts Hans Grünhagen, Olaf Ritzeler, and Georg Terstappen.

Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, provided the following corporate update:

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced its drug candidate, leronlimab, has been granted U.S. Patent No. 11,045,546 by the U.S. Patent and Trademark Office for methods of treating coronavirus infection.

Bionomics Limited, a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase 2b trial to evaluate the tablet formulation of BNC210 in patients with Post-Traumatic Stress Disorder with top line results expected in 1H 2023.

Torus Biosystems, Inc., a point of care molecular diagnostics company spun out of the Wyss Institute for Biologically Inspired Engineering at Harvard University, announced the publication of performance results for its Donut PCR system.

Tunisia is one of the rare countries in Africa having a well-established pharmaceutical sector. They have efficient and modern pharmaceuticals and such medications are considered legal in other nations.

The T-cell therapy market is anticipated to rise at a stellar growth rate for the forecast period between 2020 and 2030.

Retail clinics are the ones that provide primary healthcare services across departmental stores, supermarkets, and retail stores.

The preparative and process chromatography market is anticipated to display phenomenal growth rate over the forecast period from 2020 to 2030.